Cryoport and Minaris Regenerative Medicine Form Strategic Partnership to Support Advancement of Cell and Gene Therapies
Cryoport and Minaris Regenerative Medicine Form Strategic Partnership to Support Advancement of Cell and Gene Therapies
Partnership Will Provide Cell and Gene Therapy Industry with Fully Integrated Logistics and Manufacturing Services for Regenerative Medicine Products
合作伙伴將爲細胞和基因治療行業提供針對再生醫學產品的完全集成物流和製造服務。 納什維爾和橫濱，2024年6月20日/美通社/——全球領先的生命科學供應鏈解決方案提供商Cryoport Inc.（美國納斯達克股票代碼：CYRX）（以下簡稱“Cryoport”）與細胞和基因治療藥物的全球合同研發和製造組織Minaris再生醫學有限公司（以下簡稱“Minaris”）宣佈了一項戰略合作伙伴關係，爲生物技術和製藥公司提供針對再生醫學產品的完全集成的物流和製造服務，以支持細胞和基因治療的發展。
NASHVILLE, Tenn. and YOKOHAMA, Japan, June 20, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences, and Minaris Regenerative Medicine Co., Ltd. ("Minaris"), a global contract development and manufacturing organization for cell and gene therapies, today announced a strategic partnership to provide fully integrated logistics and manufacturing services to biotechnology and pharmaceutical companies for regenerative medicine products to support the advancement of cell and gene therapies.
合作將結合Cryoport在滿足生命科學行業物流需求方面的廣泛能力和經驗以及Minaris在再生醫學產品包括幹細胞、基因治療、生物材料和工程組織方面的合同製造專業知識。
The collaboration combines Cryoport's extensive capabilities and experience in meeting the logistics needs of the life sciences industry and Minaris' expertise in contract manufacturing of regenerative medicine products including stem cells, gene therapy, biomaterials and engineered tissue.
Cryoport首席執行官Jerrell Shelton評論道：“我們期待與Minaris合作，爲再生醫學產品提供一體化的供應鏈解決方案和製造服務，從細胞和組織的收集一直到將這些關鍵產品和服務交付給患者。這一合作伙伴關係與我們公司支持醫療社區及其服務的承諾完全一致。”
Jerrell Shelton, CEO of Cryoport, commented, "We look forward to partnering with Minaris to provide cohesive supply chain solutions and manufacturing services for regenerative medicine products, starting from the collection of cells and tissues all the way to the delivery of these critical products and services to patients. This partnership perfectly aligns with our organization's commitment to support the medical community and the people it serves."
Minaris首席執行官萬戶博人博士補充道：“確保安全的運輸，包括專用容器的使用和操作，以及質量保證，對於再生醫學產品至關重要。通過與Cryoport合作，一個在所有這些領域都擁有 considerable 資源的一流公司，我們將合作提供量身定製的高品質服務，以滿足我們客戶的精確需求。雖然這個合作是與Minaris的日本分公司合作，但我們將合作確保我們可以爲整個Minaris集團的客戶提供服務。”
Dr. Hiroto Bando, CEO of Minaris, added, "Ensuring secure transport, including the use and operation of specialized containers, as well as quality assurance, is essential for regenerative medicine products. By partnering with Cryoport, a best-in-class company that has considerable resources in all these areas, we will collaborate to provide high-quality services tailored to the exact needs of our customers. While this partnership is with Minaris' Japan-based branch, we will collaborate to ensure that we can provide services to customers across the entire Minaris group."
關於Cryoport，Inc. Cryoport，inc.（nasdaq：CYRX）是細胞和基因療法的供應鏈解決方案的全球領先者，使製造商、合同製造商（CDMO）、合同研究組織（CRO）、開發商和研究人員能夠確保自己的業務順利進行。我們爲生命科學行業提供廣泛的供應鏈解決方案。通過我們平台的關鍵產品和解決方案，包括高級溫度控制包裝、信息學、專業的生物物流服務、生物儲存、生物服務和低溫系統，我們通過我們的創新系統、符合法規的程序和敏捷的卓越供應鏈管理方式，在全球範圍內“實現未來的醫療”
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for cell & gene therapies that enable manufacturers, contract manufacturers (CDMO's), contract research organizations (CRO's), developers, and researchers to carry out their respective business with certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.
公司總部位於田納西州納什維爾，還在17個國家設有50多個全球地點，主要分佈在美國、英國、法國、荷蘭、葡萄牙、德國、日本、澳大利亞、印度和中國的重要地點。
有關更多信息，請訪問https://www.cryoport.com/或通過LinkedIn關注我們：https://www.linkedin.com/company/cryoport或通過X，以前稱爲Twitter，獲取即時更新：https://twitter.com/cryoport。
Its corporate headquarters, located in Nashville, Tennessee, is complimented by over 50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the Netherlands, Portugal, Germany, Japan, Australia, India, and China.
關於Minaris再生醫學有限公司Minaris再生醫學是一家全球的細胞和基因治療的合同研究和製造組織（CDMO）。我們的願景是共同創造未來的細胞治療奇蹟，我們致力於爲細胞和基因治療提供全球製造服務、開發解決方案和技術，以改善社會的福祉。我們爲客戶提供高價值的臨床和商業製造服務、開發解決方案和技術。我們是這個領域的先驅者，擁有超過25年的經驗，提供卓越的質量和可靠性。我們在北美、歐洲和亞洲的設施使我們能夠向全球範圍內的患者提供改變生命的療法。Minaris再生醫學完全歸Resonac Holdings Corporation所有。
For more information, visit or follow via LinkedIn at or @cryoport on X, formerly known as Twitter at for live updates.
關於Minaris的更多信息，請訪問www.minarisregenmed.com。
About Minaris Regenerative Medicine Co., Ltd.
Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. Our vision is creating future cell therapy miracles together and we are committed to providing global manufacturing services, development solutions, and technologies for cell and gene therapies to improve society's well-being. We offer our clients high value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 25 years' experience providing outstanding quality and reliability. Our facilities in North America, Europe, and Asia allow us to supply patients worldwide with life-changing therapies. Minaris Regenerative Medicine is wholly owned by Resonac Holdings Corporation.
本新聞稿中的陳述，其中不純粹是歷史的，包括Cryoport的意圖、希望、信念、期望、表現、預測、計劃或未來的預測、是美國《1995年證券訴訟改革法》中的前瞻性陳述。這些前瞻性陳述包括但不限於與Cryoport的行業、業務、長期增長前景、計劃、策略、收購、未來財務業績和財務狀況有關的陳述，例如Cryoport對於2024年全年營收的前景和指導以及推動營收的相關假設和因素、Cryoport所處市場的預計增長趨勢、Cryoport關於新產品和服務上市的預期時間和效益等方面的計劃和期望，Cryoport對其收購後未來利益的預期以及關於獲得監管批准、標籤/地理擴張或移動到早期治療線的與Cryoport客戶產品相關的預期等方面的預期。前瞻性陳述還包括Cryoport預計其營收將在全年逐步改善的預期，包括Cryoport預計其細胞和基因治療客戶的營收將逐步提升，Cryoport預計MVE的低溫系統銷售在未來的餘下時間將受到衝擊，Cryoport對其生命科學產品業務的長期前景的預期，包括需求趨於正常化，催生了Cryoport作爲全球領先者的地位，Cryoport計劃在近期推動積極的調整後的EBITDA和現金流措施，預計這將有助於2024年下半年的業績。需要注意的是，Cryoport的實際結果可能與任何此類前瞻性陳述中的實際結果有所不同。可能導致實際結果與這些前瞻性陳述不同的因素包括但不限於，與經濟和地緣政治狀況的變化、供應鏈限制、通貨膨脹壓力、外匯波動的影響、產品市場的趨勢、Cryoport的現金流變化、市場接受風險和技術發展風險有關的風險和不確定性。 Cryoport的業務可能受其他因素的影響，這些因素在Cryoport的SEC報告中討論，包括在其最近文件的10-K和10-Q表格中的“風險因素”部分，以及在其隨後提交給SEC的文件中討論。本新聞稿中包含的前瞻性陳述僅在此日期之時發表，Cryoport警告投資者不要過度依賴這些前瞻性陳述。除法律規定外，Cryoport不承諾、也無承諾更新或修改本新聞稿中的任何前瞻性陳述。
Cryoport，Inc. 是一家全球的細胞和基因治療的合同研究和製造組織（CDMO）。我們的願景是共同創造未來的細胞治療奇蹟，我們致力於爲細胞和基因治療提供全球製造服務、開發解決方案和技術，以改善社會的福祉。我們爲客戶提供高價值的臨床和商業製造服務、開發解決方案和技術。我們是這個領域的先驅者，擁有超過25年的經驗，提供卓越的質量和可靠性。我們在北美、歐洲和亞洲的設施使我們能夠向全球範圍內的患者提供改變生命的療法。Minaris Regenerative Medicine完全歸Resonac Holdings Corporation所有。
For more information about Minaris, please visit
有關Minaris的更多信息，請訪問www.minarisregenmed.com。
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as Cryoport's outlook and guidance for full year 2024 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Cryoport operates, Cryoport's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, Cryoport's expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of Cryoport's clients. Forward-looking statements also include those related to Cryoport's anticipation that its revenue will progressively improve throughout the year, including anticipated acceleration of revenue from the Cryoport's Cell & Gene Therapy clients, Cryoport's expectations that MVE's cryogenic system sales will be challenged throughout the remainder of the year, the Cryoport's expectations of the long-term prospects of its Life Sciences Products business, including the anticipation of demand normalizing, which would allow Cryoport to benefit from its position as the global leader in this space, and Cryoport's planned initiatives to drive toward positive adjusted EBITDA and cash flow in the near term, which it expects should positively impact its results of operations for the second half of 2024. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
前瞻性聲明
本新聞稿中的陳述，其中不純粹是歷史的，包括Cryoport的意圖、希望、信念、期望、表現、預測、計劃或未來的預測、是美國《1995年證券訴訟改革法》中的前瞻性陳述。這些前瞻性陳述包括但不限於與Cryoport的行業、業務、長期增長前景、計劃、策略、收購、未來財務業績和財務狀況有關的陳述，例如Cryoport對於2024年全年營收的前景和指導以及推動營收的相關假設和因素、Cryoport所處市場的預計增長趨勢、Cryoport關於新產品和服務上市的預期時間和效益等方面的計劃和期望，Cryoport對其收購後未來利益的預期以及關於獲得監管批准、標籤/地理擴張或移動到早期治療線的與Cryoport客戶產品相關的預期等方面的預期。前瞻性陳述還包括Cryoport預計其營收將逐步改善的預期，包括Cryoport預計其細胞和基因治療客戶的營收將逐步提升，Cryoport預計MVE的低溫系統銷售在未來的餘下時間將受到衝擊，Cryoport對其生命科學產品業務的長期前景的預期，包括需求趨於正常化，催生了Cryoport作爲全球領先者的地位，Cryoport計劃在近期推動積極的調整後的EBITDA和現金流措施，預計這將有助於2024年下半年的業績。需要注意的是，Cryoport的實際結果可能與任何此類前瞻性陳述中的實際結果有所不同。可能導致實際結果與這些前瞻性陳述不同的因素包括但不限於，與經濟和地緣政治狀況的變化、供應鏈限制、通貨膨脹壓力、外匯波動的影響、產品市場的趨勢、Cryoport的現金流變化、市場接受風險和技術發展風險有關的風險和不確定性。 Cryoport的業務可能受其他因素的影響，這些因素在Cryoport的SEC報告中討論，包括在其最近文件的10-K和10-Q表格中的“風險因素”部分，以及在其隨後提交給SEC的文件中討論。本新聞稿中包含的前瞻性陳述僅在此日期之時發表，Cryoport警告投資者不要過度依賴這些前瞻性陳述。除法律規定外，Cryoport不承諾、也無承諾更新或修改本新聞稿中的任何前瞻性陳述。
SOURCE Cryoport, Inc.
來源：Cryoport，Inc。
譯文內容由第三人軟體翻譯。